Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis
Loading...
Date
Authors
Georgopoulou, A. P.
Savva, A.
Giamarellos-Bourboulis, E. J.
Georgitsi, M.
Raftogiannis, M.
Antonakos, N.
Apostolidou, E.
Carrer, D. P.
Dimopoulos, G.
Economou, A.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer-reviewed
Educational material type
Conference Name
Journal name
J Crit Care
Book name
Book series
Book edition
Alternative title / Subtitle
Description
PURPOSE: The objective of this study is to define if early changes of procalcitonin (PCT) may inform about prognosis and appropriateness of administered therapy in sepsis. METHODS: A prospective multicenter observational study was conducted in 289 patients. Blood samples were drawn on day 1, that is, within less than 24 hours from advent of signs of sepsis, and on days 3, 7, and 10. Procalcitonin was estimated in serum by the ultrasensitive Kryptor assay (BRAHMS GmbH, Hennigsdorf, Germany). Patients were divided into the following 2 groups according to the type of change of PCT: group 1, where PCT on day 3 was decreased by more than 30% or was below 0.25 ng/mL, and group 2, where PCT on day 3 was either increased above 0.25 ng/mL or decreased less than 30%. RESULTS: Death occurred in 12.3% of patients of group 1 and in 29.9% of those of group 2 (P < .0001). Odds ratio for death of patients of group 1 was 0.328. Odds ratio for the administration of inappropriate antimicrobials of patients of group 2 was 2.519 (P = .003). CONCLUSIONS: Changes of serum PCT within the first 48 hours reflect the benefit or not of the administered antimicrobial therapy. Serial PCT measurements should be used in clinical practice to guide administration of appropriate antimicrobials.
Description
Keywords
Aged, Aged, 80 and over, Anti-Infective Agents/*therapeutic use, Biological Markers/blood, Calcitonin/*blood, Female, Humans, Male, Middle Aged, Odds Ratio, Practice Guidelines as Topic, Prognosis, Prospective Studies, Protein Precursors/*blood, Sepsis/*blood/*drug therapy/mortality, Time Factors, Treatment Outcome
Subject classification
Citation
Link
http://www.ncbi.nlm.nih.gov/pubmed/20869839
http://ac.els-cdn.com/S0883944110001905/1-s2.0-S0883944110001905-main.pdf?_tid=55266b6655c201c0cbbfc3dfb50e6cdb&acdnat=1333608462_ef855e5e25a4e8826ac5bf6eee01dc38
http://ac.els-cdn.com/S0883944110001905/1-s2.0-S0883944110001905-main.pdf?_tid=55266b6655c201c0cbbfc3dfb50e6cdb&acdnat=1333608462_ef855e5e25a4e8826ac5bf6eee01dc38
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής